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THE CASE FOR LIVE POLIOVIRUS VACCINATION**
Large scale programs for the control of poliomyelitis through the use
of active immunization can be said to have started, both in the United
States and elsewhere, in 1955. This step marked the end of a 40-year
period in which experimental efforts to vaccinate against poliomyelitis had
been repeatedly tried. As early as 1910, Dr. Simon Flexner, the Director
of the Rockefeller Institute, and at that time the leading United States
authority on the virus etiology of poliomyelitis, is quoted in a newspaper
as having referred to Landsteiner and Popper's recent (1908) discovery
of the virus of poliomyelitis' in the following terms: "Now that the virus
of poliomyelitis has been discovered, the development of a vaccine to pre-
vent the disease should only be a matter of months." There is no proof
that Dr. Flexner ever made such a statement, but his contemporary col-
leagues do recall his eager hopes and it is unlikely that he (or they) sus-
pected in 1910 that it would be a matter of some 540 months before such
a prediction was to be realized in any true sense of the word, and, indeed,
the search for an ideal vaccine may not yet be finished.
The many interim, albeit sporadic, attempts to develop anti-poliomyelitis
vaccines are fairly well known and started with experimental work in mon-
keys in which both killed and live virus vaccines were tried. The first of
the trials in man were those with ricineolated and formalinized vaccines.
They were not particularly successful. It was not until a few years after
the composition of the poliovirus family, consisting as it does of three
different serotypes, became knowne that Dr. Salk, working under the aus-
pices of the National Foundation for Infantile Paralysis, began his work
on a formalinized (killed) poliovirus vaccine. By 1954 the vaccine was
ready for a large-scale field trial known today as the Francis field trial.'
From that date forward, the control of poliomyelitis became a reality.
Since 1955, therefore, the record has been impressive, and the prevalence
of paralytic poliomyelitis has been appreciably reduced within areas where
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the Salk-type vaccine was adequately used.'8 * It is the only vaccine at
present approved as a method for the prevention of paralytic poliomyelitis
in the United States. Its potency has been improved recently, and the
gains which have been made in reducing the incidence of paralytic polio-
myelitis are almost certain to continue. On these bases the Salk-type vac-
cine deserves vigorous support, and campaigns to extend its use are dis-
tinctly in order. Nevertheless, as with most such prophylactic and thera-
peutic measures, techniques are liable to change. Thus there are questions
not only with regard to the ways of giving the Salk-type vaccine but also
as to whether it will be eventually replaced by a live poliovirus vaccine, or
conceivably whether there will be some sort of combination of the two."'
The ultimate aim is, and has been, of course, to reduce paralytic poliomye-
litis to the lowest possible minimum.
The case for the live poliovirus vaccine rests in part upon the idea that
an actual induced infection will produce a more solid type of immunity than
will the parenteral injection of a killed viral antigen. This suggests that
the Salk-type vaccine is not quite adequate and so one should first look
at the record of the past four years in which the Salk-type vaccine has
been used in the United States. In some areas in 1959 the efficiency of
the killed vaccine in protecting against paralytic poliomyelitis has been
rated as high as 90 per cent. And yet troublesome epidemics of poliomye-
litis occurred in certain U. S. cities in 1958 and 1959, the latter having
been a relatively bad year with more than 5,000 paralytic cases as of De-
cember 1959. Before criticizing the potency of the killed vaccine, it should
be pointed out that the major reason why paralytic poliomyelitis has not
been more markedly reduced, has been the failure, during the past four
years, of many to take advantage of the vaccine for themselves or for their
children. The vaccine itself cannot be blamed for this. In many U. S.
cities not more than half the population under 40 years of age has been
vaccinated and in the serious U. S. epidemics of 1958 and 1959 most of
those who contracted paralytic poliomyelitis either had not been vaccinated
at all or had been inadequately vaccinated. For example, in the Detroit
epidemic of 1958, only 12 per cent of the paralytic cases occurred in per-
sons who had received three doses of vaccine, whereas 73 per cent of such
* Current techniques for the administration of this vaccine call for its intramuscular
inoculation in three divided doses of 1 ml. each, the second being given one month to
six weeks after the first, and the third not earlier than seven months after the second.
To increase the efficiency of the vaccine, the Surgeon General of the U.S. Public Health
Service recommended in June 1959 that a fourth dose might be given one year after the
third. There has even been some discussion as to the possibility of recommending a
subsequent annual dose to children, but no definitive opinion has been reached on this
point which is for the future to decide.
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cases occurred in persons who had received no vaccine." In particular, it
has been among infants and young children below the age of six years and
young adults between 18 and 40 where the vaccination program has lagged.
To meet these deficiencies in the United States much attention is being
brought to bear on this problem by municipal, state, and national health
services.
In reviewing indications for the use of the Salk-type vaccine one should
consider the way that it is supposed to work, namely, that by inoculating
killed poliovirus into the body a certain degree of immunity is created
which protects the person against a subsequent severe infection with live,
virulent poliovirus. One should recall in this connection that ordinarily
almost 99 per cent of natural infections with live virulent poliovirus are
so mild as to escape notice. This is the way (i.e., from repeated mild,
inapparent infections) that most people before the days of vaccination
gained their immunity. In some persons, however, the infection with polio-
virus is severe enough to cause paralysis and this is the risk that unvac-
cinated people take. Thus the Salk-type vaccine does not prevent mild
infections with polioviruses. Its effect is to keep the immunity of the per-
son who has been vaccinated at such a level that when he does become
infected, his "case" will be mild.
Live poliovirus vaccines. Of growing interest in the world-wide cam-
paign to control paralytic poliomyelitis has been the live attenuated polio-
virus vaccine.10 The history of live poliovirus vaccines goes back almost
40 years, as far as experimental work in monkeys is concerned. In man
it goes back almost a decade. In this search Dr. Hilary Koprowski, at
that time an associate of the Lederle Laboratories of Pearl River, N. Y.,
was a pioneer." His early observations paved the way for much future
work by himself and others.5' Since 1952, a number of candidate strains
representing the three serotypes of polioviruses have been proposed and
several have been tried out on a large scale. The major investigators and
proponents in these developments besides Dr. Koprowski have been Dr.
Albert B. Sabin of the Children's Hospital Research Foundation,'7 Univer-
sity of Cincinnati Medical School, and Dr. Herald Cox of the Lederle
Laboratories.* Perhaps one of the reasons why the idea of a live polio-
virus vaccine found favor with certain immunologists has been the satis-
factory experience with live virus vaccines which has been encountered in
the field of veterinary medicine. It is also an acknowledged principle that,
by and large, a more solid type of immunity can result from an actual
* See reference 10, and many papers by H. R. Cox, B. J. Cabasso, S. S. Markham,
Roca-Garci, and others.
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infection than from the injection of a killed substance into the body. Obvi-
ously, this last statement needs qualification, because one could continue
injecting killed substances into a given person, month after month or year
after year, thereby producing a very solid kind of immunity, but such a
procedure would not be very practical. The problem then in the progran
for the control of paralytic poliomyelitis is to see, first, whether the domes-
ticated (so-called attenuated) polioviruses now being proposed to be used
as vaccines by Dr. Koprowski, Dr. Sabin, and Dr. Cox are safe; and,
secondly, whether they will confer a solid kind of immunity on the person
thus vaccinated-at least as solid if not more so than that produced by
the killed poliovirus vaccine.
The principle of this type of vaccination is obviously similar to that of
vaccination against smallpox, namely, by inducing an actual though harm-
less infection with a live, a virulent virus, related to that which causes the
serious disease, one also induces immunity to the serious disease. As the
natural portal of entry of poliovirus is through the alimentary tract, the
live poliovirus vaccines are administered by mouth instead of by injection.
Thus they might serve as agents which should be more easily administered.
They will probably be less expensive. However, whether or not they are
practical and more efficient remains to be seen.
There is evidence that the kind of immunity induced by the killed Salk-
type vaccine may differ from that of the live poliovirus vaccines. With
the former it is assumed that adequate neutralizing antibody levels are a
measure of the immunity produced and that they reflect something that
limits the spread of poliovirus within the body, thereby preventing signifi-
cant invasion of the central nervous system. There is less evidence, how-
ever, that such circulating antibodies are a measure of resistance against
subsequent implantation of the virus or penetration of the virus through
the superficial or deeper layer of the integument of the alimentary tract.
Thus the presence of artificially induced antibodies of moderate levels in
itself does not prevent subsequent alimentary infection. With the live polio-
virus vaccines, antibodies are also produced which circulate in the blood
stream, but evidence suggests that in addition there is produced some kind
of tissue resistance, or locally concentrated humoral resistance, to which
the term "local resistance" might be applied until a better name is sug-
gested. In any event, a person vaccinated (i.e., actually infected) with
live attenuated poliovirus is more apt to have developed a state of resistance
for the prevention of a reinfection with virulent polioviruses than is the
person who has received killed virus. Re-infections nonetheless do occur.
So far the attenuated poliovirus vaccines have certain advantages, but
there are complexities in their use still to be unravelled and they are still
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to be regarded, as far as the U. S. Public Health Service is concerned,
as being in an experimental stage. One feature is that the live virus vaccine
does not always take and it is not easy to know when this happens. An-
other is that anyone acutely infected with these viruses may spread the
infection to others in much the same manner that anyone with a cold might
infect his intimate associates. Thus involuntary vaccination may result,
and it is easy to see how there could be opposition on the part of the public
to this idea, perhaps comparable to the kind of objection occasionally
encountered about putting fluorides in the water supply.
As to the origin of these attenuated polioviruses, some of them have
been produced in the laboratory, others have been picked up in the so-called
"wild" state. Those which have been prepared in the laboratory have been
subjected to a process of domestication as it were. The most frequently
used method of domestication or of taming these strains of virus has been
that of starting with a virulent strain of poliovirus and growing it con-
tinuously with multiple passages in tissue cultures. What happens under
these circumstances is that the dangerous strain of poliovirus in the course
of adapting itself to a new and artificial environment may lose the property
of virulence. After prolonged transfer of this kind, often by means of the
terminal dilution techniques, the assumption has been made that this loss
of virulence becomes more or less fixed and the strain of modified virus
can be considered relatively safe for use as an immunizing agent in man.
Some of the tests employed to check this are measures of the neurovirulence
in the monkey on both intracerebral or intraspinal inoculation; there are
also a number of other measurable properties more or less related to viru-
lence, but the ultimate tests of safety, and by far the most extensive, have
been made on man. In these field trials on human populations, the objective
has been to see whether there has been any evidence of illness in those who
have received the vaccine, i.e., vaccines, or whether any illness traceable
to infection by the attenuated poliovirus has been evident among the vac-
cinee's neighbors. Surveys have also been made to see whether the domes-
ticated virus may or may not gradually work its way back to being a dan-
gerous virus during the time in which it multiplies within the body of a
single person or whether virulence becomes enhanced during natural
human-to-human passage. Obviously, if reversion to virulence occurs, this
would be an undesirable event. All one can say at present is that illness
which has been the proven result of an infection by attenuated poliovirus
given as a vaccine has to date not been noted. It has been noted nonethe-
less that attenuated virus excreted in stools occasionally shows evidence
of having undergone some changes and even to have become slightly more
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virulent than when fed. However, such viruses are still in that attenuated
range where they are relatively harmless.
In the United States small field trials have been carried out over the
past six or eight years, in New York State,'1 Ohio,'7 California,' Con-
necticut,6 Louisiana,5 and Arizona.8 A larger trial has recently been re-
ported from Minnesota.'° Many other trials have been conducted abroad,
within such countries as the Belgian Congo,' Uruguay,1' Chile,1 Colombia,10
Nicaragua,' and Mexico,0' 16 In Costa Rica, a campaign which aims to vac-
cinate all the children under 13 years of age has been in progress during
1959.103 In Europe, trials have been carried out in Holland,' England,'
Finland,'0 Poland,10 and Czechoslovakia.10 It is certain that others not men-
tioned here have also been done. However, the most extensive and signifi-
cant of the large-scale tests are those which have been carried out in 1959
in the Soviet Union.10 This program now involves 11 of the 15 Soviet
Republics and covers about 10,000,000 individuals. Plans are underway
to enlarge these to 15,000,000 before 1960 and perhaps 60,000,000 by 1961.'
The results so far seem to be satisfactory and among the millions of per-
sons, including infants, children, and adults, who have received this vac-
cine to date there has not been a single unfavorable report.
Nonetheless, quite a few questions still remain to be answered about the
live vaccine. How many individuals, particularly the children who have
received the vaccine, are actually immunized as a result of this experience
is a question with high priority. It appears that this measure of efficiency
differs in different environments. Without laboratory tests it is impossible
to determine whether a "take" has occurred or not. Failure to take can
be due to several factors. The phenomenon of interference, for instance,
can be one of them-interference not only by wild polioviruses but by other
enteroviruses. At the present time trials are being conducted to determine
whether by increasing the dosage this deficiency can be overcome.
One may ask here, with justification, why is there any need for a new
poliomyelitis vaccine if the Salk-type vaccine is successful and will con-
tinue to be used and if there are so many unknowns with regard to live
poliovirus vaccine? A primary answer to this is that, after all, it is logical
that a search for improvements in methods of protecting against this seri-
ous disease should continue. As mentioned earlier in this article, the Salk-
type vaccine has not been found to protect all those to whom it has been
given in three doses. In the U.S.A. in 1959 this could amount to 10 or 15
per cent of the 5,000 or more reported paralytic cases. As the ultimate
objective is to protect all by methods that will prove practical, a search
for improvements should continue. Furthermore, the Salk-type vaccine
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is still moderately expensive for some countries, notably several in Latin
America and elsewhere, which might wish to use this vaccine on a large
scale but have claimed that they cannot afford to do so. This may not be
a valid criticism, for the cost of the live poliovirus vaccine is as yet an
unknown quantity. Another criticism of the Salk-type vaccine is that the
way in which it is necessary to give it-two inoculations four to six weeks
apart with a third not earlier than seven months later, and a fourth a year
after the third dose-is a difficult schedule for some people to follow. The
lag in persuading people in the United States to take advantage of the Salk-
type vaccine and to follow the proper schedule suggests that an equal or
greater task might exist in those countries less attuned to the idea of
prophylactic inoculations than is the United States. The live poliovirus
given by mouth (three times, a month apart, for the monovalent live vaccine
or perhaps not more than twice a month or six weeks apart for the triva-
lent) sounds easier administratively. It may be important to find out
whether that fraction of the U. S. population which has refused or failed
to take advantage of the Salk-type vaccine will also refuse or not even
be interested in the live poliovirus vaccine. Thus it remains to be seen
whether the live attenuated poliovirus vaccine will better the record of
Salk-type vaccine. The suggestion that it might is a challenge worth accept-
ing. As a hypothetical means of promoting the universal administration of
live poliovirus vaccine it has even been suggested, and this is under trial,
that following an initial and vigorous campaign in the local use of this
vaccine for children and young adults it might then be given to all new-
born babies and by this means the immunity of the entire population could
consequently be kept up. It remains to be seen whether parents or hos-
pitals would accept this responsibility or indeed whether newborn babies
would be sufficiently easily infected. The chances of their having interfer-
ing enteroviruses during the first days of life would seem slim but infants
may have a natural form of resistance which might be difficult to overcome
in order to get a take. It is easy to see how all these important questions
demand vigorous attention and extensive trials. In any event, if untoward
incidents or deficiencies are to occur, it is far better to have them occur
during the trial stage than afterwards when the vaccine has been approved
and licensed.
In the meantime it seems unlikely that the people of the United States will
quickly abandon the Salk-type vaccine in favor of a new product, particu-
larly as the former is being steadily improved. However, during the next few
years at least there may be an increasing use of a combination of the two,
i.e., a course of killed vaccine followed by live vaccine. Theoretically this
might yield a higher degree of protection than the use of either vaccine alone.
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To summarize the present situation, we face the fact that the only recog-
nized and official prophylactic agent against poliomyelitis in the United
States is the Salk-type vaccine. Its continued and wider use should not
only be encouraged here but urged. The live poliovirus vaccine should
be regarded as something of considerable promise which is still in the trial
stage. The present results of field trials, some of which have been very
extensive, are sufficiently encouraging to indicate that they should proceed
with dispatch if this promising new prophylactic measure is to have the
widespread use it may ultimately deserve.
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